Retrospective Collection of Data on Patient With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Y90 Ibritumomab Tiuxetan Radioimmunotherapy Plus High-Dose Chemotherapy and Autologous Stem Cell Transplant
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2018
Price : $35 *
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 11 Sep 2018 New trial record
- 01 Sep 2018 Primary endpoint (Progression Free Survival) has been met, according to results published in the Annals of Hematology.
- 01 Sep 2018 Primary endpoint . (Overall Survival) has been met, according to results published in the Annals of Hematology.